Blogs

Trial Site News features the latest coverage of clinical research. Read the article here:

The Bot Image team has been hard at work trying to obtain FDA clearance. We’re excited to announce that we have passed the first major milestone on July 21, 2020.

We’re proud to announce that in partnership with our beta testing site, we processed our first test case using the cloud-based architecture on 6/18/2020.

We recently sat down with our CEO in his library to discuss the mission, vision, and values of Bot Image. We discussed ProstatID and the…

We recently sat down with our founder to ask 10 questions about the company, the industry, and what are the options men have when facing…

A prostate cancer diagnosis can be devastating news for the one in seven men who develop the disease in their lifetimes. Annually, 30,000…

AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.

Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer SCREENING, Detection and Diagnostic AI software. With 94% AUROC (Area under

Randall W. Jones, D.Eng. (PhD, MBA) EARLY DETECTION through Screening Population-Based Screening Studies Screening for Prostate Cancer (PCa) continues to

Introduction Prostate cancer is a significant concern for men, especially as they age. Early detection is crucial for effective treatment

Prostate cancer is one of the most common cancers affecting men worldwide. However, despite its prevalence, there is still considerable

Unveiling the Silent Threat Prostate cancer is a topic that many shy away from, yet understanding its early warning signs

Prostate cancer is one of the most common cancers among men worldwide, making early detection vital for effective treatment. Understanding

Introduction Prostate cancer is a significant health concern for men worldwide. Early detection is crucial for successful treatment and better

Prostate cancer is one of the most common cancers affecting men worldwide. Early detection plays a crucial role in managing

Introduction Prostate cancer is a significant health concern for many men worldwide. It is the second most common cancer among

Understanding how doctors determine the stage and aggressiveness of prostate cancer is crucial for patients and their loved ones. This

Prostate cancer is one of the most common forms of cancer in men, and early detection is critical to improving

Most prostate cancers are either detected too late or over-diagnosed too early. For decades, the diagnostic pathway has been a

For years, contrast-enhanced MRI has been a cornerstone of prostate cancer diagnostics. While powerful, this approach is not without its

Adopting artificial intelligence in radiology should be straightforward, yet many systems introduce frustrating complexity. New workstations, manual uploads, and complicated

Every artificial intelligence company claims to offer “high accuracy.” It has become a baseline marketing promise in a crowded field.

Data is one thing—clinical impact is another. In medical imaging, performance metrics and accuracy statistics are essential, but they only

When experience varies, outcomes do too. This is a fundamental challenge in diagnostic medicine, and nowhere is it more apparent

The “wait and see” approach to medicine carries a hidden but staggering financial weight, particularly in oncology. For prostate cancer,

Many imaging centers hesitate to adopt artificial intelligence, and for good reason. The fear of vendor lock-in, complex integrations, and

In prostate cancer care, detection is only the first step. Many AI tools can flag a suspicious area on an

A breakthrough in one area of medicine often serves as the blueprint for innovation in many others. With ProstatID™, we